Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Zocor U.S. Sales Headed Past $3 Bil.: Company Sees 20% Growth

Executive Summary

U.S. sales of Zocor appear on track to top $3 bil. in 2000 based on projections of 20% growth for the full year.

You may also be interested in...



Searle To Discuss Adding Celebrex 13-Month Safety Data To Label With FDA

Searle plans to approach FDA with data from a 13-month trial comparing the ulcer incidence for Celebrex to other nonsteroidal anti-inflammatory drugs, seeking a label change for the COX-2 inhibitor.

P&G/Aventis Actonel Is Priced At 10% Discount To Merck Fosamax

Procter & Gamble and marketing partner Aventis will set the price of its Actonel dose for osteoporosis at a discount to Merck's Fosamax.

New Merck Research VP Greene Has Advisory Committee Experience

Douglas Greene, MD, joins Merck Research Laboratories as executive VP-clinical sciences & product development with prior experience serving on FDA's Endocrinologic & Metabolic Drugs Advisory Committee.

Related Content

UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel